It's a great buy, and not as "speccie" as most biotechs.~ We...

It's a great buy, and not as "speccie" as most biotechs.

~ We know it is safe & works - as proved by Japan & its trials.

~ We know the US government will want to stockpile it - as proved by the BARDA funding.

~ We know we have enough cash - over $70m in the bank and income from two sources (Relenza will probably be prefered more than Tamiflu when governments are restocking soon, due to tamiflu resistance).

And there's other products which could make good money too.

There's still risk, but a great reward to risk ratio, imho.